These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1554 related items for PubMed ID: 27468093

  • 1. Obeticholic acid for the treatment of primary biliary cholangitis.
    Ali AH, Lindor KD.
    Expert Opin Pharmacother; 2016 Sep; 17(13):1809-15. PubMed ID: 27468093
    [Abstract] [Full Text] [Related]

  • 2. Primary Biliary Cholangitis: Medical and Specialty Pharmacy Management Update.
    Bowlus CL, Kenney JT, Rice G, Navarro R.
    J Manag Care Spec Pharm; 2016 Oct; 22(10-a-s Suppl):S3-S15. PubMed ID: 27700211
    [Abstract] [Full Text] [Related]

  • 3. Investigational drugs in phase II clinical trials for primary biliary cholangitis.
    Silveira MG, Lindor KD.
    Expert Opin Investig Drugs; 2017 Oct; 26(10):1115-1121. PubMed ID: 28836457
    [Abstract] [Full Text] [Related]

  • 4. Old and new treatments for primary biliary cholangitis.
    Chascsa D, Carey EJ, Lindor KD.
    Liver Int; 2017 Apr; 37(4):490-499. PubMed ID: 28371104
    [Abstract] [Full Text] [Related]

  • 5. Finding the cure for primary biliary cholangitis - Still waiting.
    Tanaka A, Gershwin ME.
    Liver Int; 2017 Apr; 37(4):500-502. PubMed ID: 28371099
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Primary biliary cholangitis: Old and novel therapy.
    Floreani A, Mangini C.
    Eur J Intern Med; 2018 Jan; 47():1-5. PubMed ID: 28669591
    [Abstract] [Full Text] [Related]

  • 8. Management of cholestatic disease in 2017.
    de Vries E, Beuers U.
    Liver Int; 2017 Jan; 37 Suppl 1():123-129. PubMed ID: 28052628
    [Abstract] [Full Text] [Related]

  • 9. The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines.
    Hirschfield GM, Dyson JK, Alexander GJM, Chapman MH, Collier J, Hübscher S, Patanwala I, Pereira SP, Thain C, Thorburn D, Tiniakos D, Walmsley M, Webster G, Jones DEJ.
    Gut; 2018 Sep; 67(9):1568-1594. PubMed ID: 29593060
    [Abstract] [Full Text] [Related]

  • 10. Treatment of primary biliary cholangitis ursodeoxycholic acid non-responders: A systematic review.
    Suraweera D, Rahal H, Jimenez M, Viramontes M, Choi G, Saab S.
    Liver Int; 2017 Dec; 37(12):1877-1886. PubMed ID: 28517369
    [Abstract] [Full Text] [Related]

  • 11. Management of primary biliary cholangitis prior to obeticholic acid availability.
    Durazzo M, Bonetto S, Fagoonee S, Morgando A, Pellicano R.
    Minerva Med; 2018 Dec; 109(6):410-417. PubMed ID: 30022645
    [Abstract] [Full Text] [Related]

  • 12. From pathogenesis to novel therapies in the treatment of primary biliary cholangitis.
    Ronca V, Carbone M, Bernuzzi F, Malinverno F, Mousa HS, Gershwin ME, Invernizzi P.
    Expert Rev Clin Immunol; 2017 Dec; 13(12):1121-1131. PubMed ID: 28994348
    [Abstract] [Full Text] [Related]

  • 13. Long-term clinical impact and cost-effectiveness of obeticholic acid for the treatment of primary biliary cholangitis.
    Samur S, Klebanoff M, Banken R, Pratt DS, Chapman R, Ollendorf DA, Loos AM, Corey K, Hur C, Chhatwal J.
    Hepatology; 2017 Mar; 65(3):920-928. PubMed ID: 27906472
    [Abstract] [Full Text] [Related]

  • 14. Novel Aspects in the Management of Cholestatic Liver Diseases.
    Chazouillères O.
    Dig Dis; 2016 Mar; 34(4):340-6. PubMed ID: 27170387
    [Abstract] [Full Text] [Related]

  • 15. Therapy of Primary Biliary Cirrhosis: Novel Approaches for Patients with Suboptimal Response to Ursodeoxycholic Acid.
    Parés A.
    Dig Dis; 2015 Mar; 33 Suppl 2():125-33. PubMed ID: 26642350
    [Abstract] [Full Text] [Related]

  • 16. Advances in pharmacotherapy for primary biliary cirrhosis.
    Mousa HS, Lleo A, Invernizzi P, Bowlus CL, Gershwin ME.
    Expert Opin Pharmacother; 2015 Apr; 16(5):633-43. PubMed ID: 25543678
    [Abstract] [Full Text] [Related]

  • 17. Novel and emerging therapies for cholestatic liver diseases.
    Goldstein J, Levy C.
    Liver Int; 2018 Sep; 38(9):1520-1535. PubMed ID: 29758112
    [Abstract] [Full Text] [Related]

  • 18. The challenges of primary biliary cholangitis: What is new and what needs to be done.
    Terziroli Beretta-Piccoli B, Mieli-Vergani G, Vergani D, Vierling JM, Adams D, Alpini G, Banales JM, Beuers U, Björnsson E, Bowlus C, Carbone M, Chazouillères O, Dalekos G, De Gottardi A, Harada K, Hirschfield G, Invernizzi P, Jones D, Krawitt E, Lanzavecchia A, Lian ZX, Ma X, Manns M, Mavilio D, Quigley EM, Sallusto F, Shimoda S, Strazzabosco M, Swain M, Tanaka A, Trauner M, Tsuneyama K, Zigmond E, Gershwin ME.
    J Autoimmun; 2019 Dec; 105():102328. PubMed ID: 31548157
    [Abstract] [Full Text] [Related]

  • 19.
    ; 2017 08. PubMed ID: 30525349
    [Abstract] [Full Text] [Related]

  • 20. Obeticholic acid in primary biliary cholangitis: where we stand.
    Manne V, Kowdley KV.
    Curr Opin Gastroenterol; 2019 May; 35(3):191-196. PubMed ID: 30844895
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 78.